{
    "clinical_study": {
        "@rank": "1335", 
        "acronym": "Odyssey FH II", 
        "arm_group": [
            {
                "arm_group_label": "Regimen 1", 
                "arm_group_type": "Experimental", 
                "description": "LMT (atorvastatin, simvastatin, or rosuvastatin) and alirocumab (REGN727/ SAR236553)"
            }, 
            {
                "arm_group_label": "Regimen 2", 
                "arm_group_type": "Active Comparator", 
                "description": "LMT (atorvastatin, simvastatin, or rosuvastatin) and placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind, placebo-controlled, parallel-group, multi-national study\n      alirocumab (REGN727/ SAR236553) in patients with Heterozygous Familial Hypercholesterolemia\n      (heFH) who are not adequately controlled with their Lipid-Modifying Therapy (LMT)."
        }, 
        "brief_title": "Study of Alirocumab (REGN727/ SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Heterozygous Familial Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": [
                "Hypercholesterolemia", 
                "Hyperlipoproteinemia Type II"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients with heFH who are not adequately controlled with their LMT\n\n        Exclusion Criteria:\n\n          1. Age less than 18 years or legal age of adulthood, whichever is greater\n\n          2. LDL-C less than 70 mg/dL (1.81 mmol/L) and with cardiovascular disease\n\n          3. LDL-C less than 100 mg/dL (2.59 mmol/L) and without cardiovascular disease\n\n          4. Fasting serum triglycerides greater than 400 mg/dL (4.52 mmol/L)\n\n          5. Known history of homozygous familial hypercholesterolemia\n\n        (The inclusion/exclusion criteria provided above is not intended to contain all\n        considerations relevant to a patient's potential participation in this clinical trial)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "249", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01709500", 
            "org_study_id": "R727-CL-1112"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Regimen 1", 
                    "Regimen 2"
                ], 
                "intervention_name": "LMT (atorvastatin, simvastatin, or rosuvastatin)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Regimen 1", 
                "intervention_name": "alirocumab (REGN727/ SAR236553)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Regimen 2", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Simvastatin", 
                "Atorvastatin", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 25, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hradec Kralove", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 2", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 5", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 8", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Trutnov", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vyskov", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Alkmaar", 
                        "country": "Netherlands"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Apeldoorn", 
                        "country": "Netherlands"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Enschede", 
                        "country": "Netherlands"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goes", 
                        "country": "Netherlands"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Groningen", 
                        "country": "Netherlands"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hoogeveen", 
                        "country": "Netherlands"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hoorn", 
                        "country": "Netherlands"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sittard- Geleen", 
                        "country": "Netherlands"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht (2 locations)", 
                        "country": "Netherlands"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Venlo", 
                        "country": "Netherlands"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Waalwijk", 
                        "country": "Netherlands"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oslo", 
                        "country": "Norway"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cardiff", 
                        "country": "United Kingdom"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Middlesex", 
                        "country": "United Kingdom"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newcastle upon Tyne", 
                        "country": "United Kingdom"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Bromwich", 
                        "country": "United Kingdom"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Czech Republic", 
                "Netherlands", 
                "Norway", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy", 
        "overall_official": {
            "affiliation": "Regeneron Pharmaceuticals", 
            "last_name": "Dan Gipe, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Czech Republic: State Institute for Drug Control", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Norway: Norwegian Medicines Agency", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The percent change in calculated LDL-C (low-density lipoprotein cholesterol) from baseline to week 24", 
            "measure": "Percent change in LDL-C to week 24", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Wk 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01709500"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The percent change in calculated LDL-C from baseline to weeks 12 and 52.", 
                "measure": "Percent change in LDL-C to weeks 12 and 52.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Wks 12 and 52"
            }, 
            {
                "description": "The percent change in ApoB, non-HDL-C, total-C, HDL-C, Lp(a), TG, and Apo A-1 from baseline to weeks 12 and 24.", 
                "measure": "Percent change in ApoB, non-HDL-C, total-C, HDL-C, Lp(a), TG, and Apo A-1", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Wks 12 and 24"
            }, 
            {
                "description": "The proportion of patients reaching LDL-C goal at week 24", 
                "measure": "Proportion of patients reaching LDL-C goal", 
                "safety_issue": "No", 
                "time_frame": "At Wk 24"
            }, 
            {
                "description": "The proportion of patients reaching LDL-C <70 mg/dL (1.81 mmol/L) at week 24", 
                "measure": "Proportion of patients reaching LDL-C <70 mg/dL (1.81 mmol/L)", 
                "safety_issue": "No", 
                "time_frame": "At Wk 24"
            }
        ], 
        "source": "Regeneron Pharmaceuticals", 
        "sponsors": {
            "collaborator": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}